Cláudia Ramos
A5085026278- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Aging, Health, and Disability
- Genomics and Rare Diseases
- Long-Term Effects of COVID-19
- Psychological Treatments and Disorders
- Inflammatory Bowel Disease
- Health Systems, Economic Evaluations, Quality of Life
- Tryptophan and brain disorders
- COVID-19 and Mental Health
- Health and Medical Education
- Environmental Sustainability and Education
- Environmental Education and Sustainability
- Microscopic Colitis
- Public Health and Social Inequalities
- Phagocytosis and Immune Regulation
- Psychology Research and Bibliometrics
- Liver Disease Diagnosis and Treatment
- Cholinesterase and Neurodegenerative Diseases
- Autism Spectrum Disorder Research
- Nanoparticle-Based Drug Delivery
- Child and Adolescent Psychosocial and Emotional Development
- Business, Innovation, and Economy
- Functional Brain Connectivity Studies
- Accounting and Financial Management
Universidad de Antioquia
2016-2025
Therapeutics Clinical Research
2022-2023
Alzheimer’s Disease Neuroimaging Initiative
2015-2023
Universidad Cooperativa de Colombia
2022
Ação Educativa
2022
University of Pittsburgh
2015-2021
Global Brain Health Institute
2020-2021
Mirati Therapeutics (United States)
2021
University of California, San Francisco
2020
Universidad Nacional José Faustino Sánchez Carrión
2020
Abstract Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes—aggregation amyloid-β (Aβ) peptide into plaques and microtubule protein tau neurofibrillary tangles (NFTs)—are hallmarks disease. However, other brain processes are thought to be key mediators Aβ plaque NFT pathology. How these additional pathologies evolve over course is currently unknown. Here we show that proteomic measurements in autosomal dominant AD...
Autosomal-dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify course cognitively unimpaired individuals at high imminent risk developing symptoms due to (AD), is, who have "preclinical" AD. Crenezumab is an antiamyloid monoclonal antibody binds monomeric and aggregated forms of amyloid β, with highest affinity oligomers; it in development early stages sporadic AD ADAD.
Abstract Across Latin American and Caribbean countries (LACs), the fight against dementia faces pressing challenges, such as heterogeneity, diversity, political instability, socioeconomic disparities. These can be addressed more effectively in a collaborative setting that fosters open exchange of knowledge. In this work, Consortium on Dementia (LAC‐CD) proposes an agenda for integration to deliver Knowledge Action Framework (KtAF). First, we summarize evidence‐based strategies (epidemiology,...
Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization the trajectories cerebral amyloid-β (Aβ) and tau accumulation in decades prior to clinical symptom onset. Longitudinal rates regional measured with positron emission tomography (PET) their relationship other biomarker cognitive changes remain be fully characterized ADAD.Fourteen ADAD mutation carriers (Presenilin-1 E280A) 15 age-matched non-carriers from Colombian kindred underwent 2-3 sessions Aβ...
TPS765 Background: PT886 is a novel bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD47. CLDN18.2 overexpressed in significant proportion of gastric pancreatic adenocarcinomas its restricted expression makes it promising therapeutic target for the treatment these carcinomas. Moreover, studies have found immunoglobulin superfamily CD47 widely across tumor types, plays an important role suppressing phagocytes activity through binding to transmembrane protein SIRPα phagocytic...
This paper aims to describe the experience of nursing team at Neurosciences Group Antioquia (GNA) in providing care participants Alzheimer’s Prevention Initiative (API) clinical trial Colombia, highlighting professional role healthcare providers from a perspective. It reports on research that examines management and provided by GNA team, framed within principles health promotion disease prevention. Through this work, demonstrates how becomes act, grounded standards profession.
El presente artículo tiene el objetivo de describir la experiencia del equipo enfermería Grupo Neurociencias Antioquia (GNA) en atención a participantes ensayo clínico Alzheimer’s Prevention Initiative (API) Colombia y resaltar dimensión profesional área salud desde enfermería. Este es un reporte que se describe manejo brindada por GNA, enmarcados dentro los principios promoción prevención enfermedad. A través su trabajo, demuestra cómo cuidado convierte acto profesional, fundamentado...
The amygdala plays a role in behavior and emotional response is vulnerable to Alzheimer's disease (AD) pathology, yet little known about tau accumulation before clinical symptom onset. To investigate whether certain nuclei are particularly degeneration might underlie early neuropsychiatric symptoms AD, we aimed characterize subregional pathology its correlates associations with established biomarkers of AD cognitive-behavioral measures Presenilin-1 E280A mutation carriers autosomal dominant...
Abstract INTRODUCTION This study involved evaluating a tailored genetic counseling and testing (GCT) protocol for families at risk of autosomal dominant Alzheimer's disease (ADAD) in Latin America (LatAm), focusing on essential cultural regional adaptations. METHODS We conducted non‐randomized controlled trial among ADAD Colombia Argentina. Participants were categorized based their decision to learn status (GS), with further comparisons between mutation‐positive versus mutation‐negative...
Summary The Colombian Alzheimer's Prevention Initiative (API) Registry is a collaborative project among the Neurosciences Group of Antioquia, Banner Institute, and Genentech. main goal to provide source interested research participants data support API‐Colombia Autosomal Dominant Disease Trial help find treatments delay or prevent clinical onset disease.
BackgroundNeuroimaging studies often quantify tau burden in standardized brain regions to assess Alzheimer disease (AD) progression. However, this method ignores another key biological process which spreads additional regions. We have developed a metric for calculating the extent pathology has spread throughout and evaluate relationship between across early stages of AD.Methods445 cross-sectional participants (aged ≥ 50) who had MRI, amyloid PET, clinical testing were separated into...
Abstract Background Most neurological diseases have no curative treatment; therefore, focusing on prevention is key. Continuous research to uncover the protective and risk factors associated with different crucial successfully inform strategies. eHealth has been showing promising advantages in healthcare public health may therefore be relevant facilitate epidemiological studies. Objective In this study, we performed a Delphi consensus exercise identify key screening tests development of...
Graphene is a two-dimensional network of carbon atoms with optimal thermal, electronic and chemical stability properties that promise different versatile applications in various fields including the protection metals from corrosion phenomena. For this reason paper graphene was employed studied as an agent dopand incorporated into hybrid sol-gel coatings to enhance their resistance saline media improve durability these films. obtained by using electrochemical method involving oxidation...
Abstract Background Cerebrospinal fluid (CSF) biomarkers have potentially important roles in Alzheimer’s disease (AD) treatment and prevention trials. The Prevention Initiative Autosomal‐Dominant AD (API ADAD) trial protocol (NCT01998841) includes optional CSF biomarker measurements at baseline, 24 months, 60 months. We determined the adherence to lumbar puncture (LP) procedures predictors of dropout rates participants who had a baseline LP. Method Available data from cognitively unimpaired...
Abstract Background Neuropsychiatric symptoms (NPS) are common in early stages of Alzheimer’s disease (AD) and may be markers cognitive decline dementia older individuals. The Mild Behavioral Impairment Checklist (MBI‐C) was developed to capture new‐onset transdiagnostic NPS individuals at risk dementia. We sought determine whether mild behavioral impairment elevated non‐demented Presenilin‐1 (PSEN1) E280A carriers, who genetically determined develop by their 50s. hypothesized that those...
TPS365 Background: Sitra is a spectrum-selective receptor tyrosine kinase inhibitor (TKI) that targets TAM receptors (TYRO3, AXL, MERTK), VEGFR2, c-Kit, and c-MET. has shown antitumor activity in accRCC, reduces type 2 tumor-associated macrophages, regulatory T-cells myeloid-derived suppressor cells enhances T cell–mediated immune responses. The combination of sitra with anti-PD1 checkpoint inhibitors (ICIs), such as nivo, an acceptable safety profile demonstrates efficacy across multiple...
Background: Cigarette smoking is a known risk factor for Alzheimer’s disease (AD). However, the association between neurodegeneration and other substances has not been fully determined. It of vital importance to evaluate this relationship in populations at high dementia. Since substance use possibly modifies progression rate cognitive decline, we studied unique well-phenotyped cohort from University Antioquia: carriers PSEN1-E280A genetic variant. Objective: To determine decline Methods: A...